{
  "asset": {
    "name": "TransCon hGH",
    "company": "Ascendis Pharma",
    "ticker": "ASND",
    "target": "Growth hormone pathway",
    "mechanism": "Growth hormone therapy that presses the accelerator by recruiting stem cells and increasing chondrocyte numbers",
    "modality": "TransCon prodrug technology",
    "partner": null
  },
  "clinical_development": {
    "current_stage": "Phase 2",
    "indications_in_development": [
      "Achondroplasia (combination therapy)",
      "Additional growth disorders"
    ]
  },
  "trials": [],
  "investment_thesis": [
    "Well-positioned to be the leader in growth disorders with once-weekly TransCon CNP and TransCon hGH"
  ],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    3,
    5,
    17
  ],
  "_last_extracted": "2026-02-04T13:31:56.900163"
}